Subscribe To

Price Alert Latest News Economic Calendar News

CERE / Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 4th Annual CNS Day on Tuesday, March 29, 2022 at 9:00 a.m. EDT. Read More

Demo Live Account See Partner Details

Content Topics

Cerevel

Therapeutics

Present

Stifel

Annual

Event

Stock

CERE

Posted: Mar 21 2022, 06:30

Author Name: GlobeNewsWire

CERE News

By GlobeNewsWire
October 13, 2023

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain

By GlobeNewsWire
August 29, 2023

Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain

By The Motley Fool
August 2, 2023

Why Shares of Cerevel Therapeutics Are Dropping Wednesday

Cerevel said it is experiencing delays in some of its clinical trials. The company appointed a new CEO in June.

By GlobeNewsWire
July 5, 2023

Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023

CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain

By Seeking Alpha
June 4, 2023

Cerevel: High Priced Stock Doing Interesting Science

Cerevel has some interesting data in various CNS indications. However, the company has a very high valuation. It seems a lot of the company's potentia

By Seeking Alpha
May 7, 2023

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2023 Earnings Call Transcript

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Matthew Calistri - Vic

By GlobeNewsWire
February 1, 2023

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain

By GlobeNewsWire
January 9, 2023

Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indicati

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.